SI3555105T1 - Spojine 7-feniletilamino-4H-pirimido(4,5-D)(1,3)oksazin-2-ona kot inhibitorji mutiranih IDH1 in IDH2 - Google Patents
Spojine 7-feniletilamino-4H-pirimido(4,5-D)(1,3)oksazin-2-ona kot inhibitorji mutiranih IDH1 in IDH2Info
- Publication number
- SI3555105T1 SI3555105T1 SI201730488T SI201730488T SI3555105T1 SI 3555105 T1 SI3555105 T1 SI 3555105T1 SI 201730488 T SI201730488 T SI 201730488T SI 201730488 T SI201730488 T SI 201730488T SI 3555105 T1 SI3555105 T1 SI 3555105T1
- Authority
- SI
- Slovenia
- Prior art keywords
- phenylethylamino
- pyrimido
- oxazin
- compounds
- mutant idh1
- Prior art date
Links
- USFRTQXJZLVVJL-UHFFFAOYSA-N 7-(2-phenylethylamino)-1,4-dihydropyrimido[4,5-d][1,3]oxazin-2-one Chemical class C1(=CC=CC=C1)CCNC=1N=CC2=C(NC(OC2)=O)N=1 USFRTQXJZLVVJL-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662435283P | 2016-12-16 | 2016-12-16 | |
| PCT/US2017/065246 WO2018111707A1 (en) | 2016-12-16 | 2017-12-08 | 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant idh1 and idh2 inhibitors |
| EP17822882.1A EP3555105B1 (en) | 2016-12-16 | 2017-12-08 | 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant idh1 and idh2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3555105T1 true SI3555105T1 (sl) | 2020-12-31 |
Family
ID=60888651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201730488T SI3555105T1 (sl) | 2016-12-16 | 2017-12-08 | Spojine 7-feniletilamino-4H-pirimido(4,5-D)(1,3)oksazin-2-ona kot inhibitorji mutiranih IDH1 in IDH2 |
Country Status (37)
| Country | Link |
|---|---|
| US (3) | US11001596B2 (sl) |
| EP (2) | EP3763717B1 (sl) |
| JP (1) | JP6793836B2 (sl) |
| KR (1) | KR102276022B1 (sl) |
| CN (2) | CN115109075B (sl) |
| AU (2) | AU2017378060B2 (sl) |
| CA (1) | CA3045303C (sl) |
| CL (1) | CL2019001551A1 (sl) |
| CO (1) | CO2019005287A2 (sl) |
| CR (1) | CR20190252A (sl) |
| CY (1) | CY1123577T1 (sl) |
| DK (1) | DK3555105T3 (sl) |
| DO (1) | DOP2019000163A (sl) |
| EA (1) | EA036112B1 (sl) |
| EC (1) | ECSP19042682A (sl) |
| ES (2) | ES2941631T3 (sl) |
| HR (1) | HRP20201882T1 (sl) |
| HU (1) | HUE052067T2 (sl) |
| IL (1) | IL267236B (sl) |
| JO (1) | JOP20190142B1 (sl) |
| LT (1) | LT3555105T (sl) |
| MA (2) | MA47399B1 (sl) |
| MD (1) | MD3555105T2 (sl) |
| MX (1) | MX2019006830A (sl) |
| MY (1) | MY197313A (sl) |
| NZ (1) | NZ754115A (sl) |
| PE (1) | PE20190977A1 (sl) |
| PH (1) | PH12019501328B1 (sl) |
| PL (1) | PL3555105T3 (sl) |
| PT (1) | PT3555105T (sl) |
| RS (1) | RS61108B1 (sl) |
| SA (1) | SA519401897B1 (sl) |
| SI (1) | SI3555105T1 (sl) |
| TN (1) | TN2019000158A1 (sl) |
| UA (1) | UA123640C2 (sl) |
| WO (1) | WO2018111707A1 (sl) |
| ZA (1) | ZA201903125B (sl) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3447050T (lt) | 2014-09-19 | 2020-05-11 | Forma Therapeutics, Inc. | Piridin-2(1h)-ono chinolinono dariniai, kaip mutantinės izocitrato dehidrogenazės inhibitoriai |
| MX373789B (es) | 2014-09-19 | 2025-03-04 | Forma Therapeutics Inc | Derivados de piridinil quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh). |
| JP6648116B2 (ja) | 2014-09-19 | 2020-02-14 | フォーマ セラピューティクス，インコーポレイテッド | 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのキノリノンピリミジン組成物 |
| CA2961807A1 (en) | 2014-09-19 | 2016-03-24 | Forma Therapeutics, Inc. | Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| US10294206B2 (en) | 2015-04-21 | 2019-05-21 | Forma Tm2, Inc. | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| US9624216B2 (en) | 2015-04-21 | 2017-04-18 | Forma Therapeutics, Inc. | Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors |
| UA125824C2 (uk) | 2016-10-24 | 2022-06-15 | Астразенека Аб | 6,7,8,9-ТЕТРАГІДРО-3H-ПІРАЗОЛО[4,3-f]ІЗОХІНОЛІНОВІ ПОХІДНІ, ЗАСТОСОВНІ В ЛІКУВАННІ РАКУ |
| JOP20190144A1 (ar) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز |
| HRP20220885T1 (hr) | 2016-12-16 | 2022-12-09 | Janssen Pharmaceutica Nv | Spojevi imidazo[4,5-d]pirolo[2,3-b]piridina kao inhibitori janus kinaze |
| CN115109075B (zh) * | 2016-12-16 | 2024-09-20 | 伊莱利利公司 | 突变体idh1和idh2抑制剂 |
| US10221173B2 (en) | 2017-01-30 | 2019-03-05 | Astrazeneca Ab | Chemical compounds |
| US11013734B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation |
| US11311527B2 (en) | 2018-05-16 | 2022-04-26 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) |
| US11013733B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1) |
| US10532047B2 (en) | 2018-05-16 | 2020-01-14 | Forma Therapeutics, Inc. | Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
| US11576906B2 (en) | 2018-05-16 | 2023-02-14 | Forma Therapeutics, Inc. | Inhibiting mutant IDH-1 |
| TW202016110A (zh) | 2018-06-15 | 2020-05-01 | 比利時商健生藥品公司 | Ｊａｋ激酶家族之小分子抑制劑 |
| EP4055015B1 (en) * | 2019-11-08 | 2025-04-02 | Nerviano Medical Sciences S.r.l. | Gem-disubstituted heterocyclic compounds and their use as idh inhibitors |
| CN115335059A (zh) * | 2020-03-23 | 2022-11-11 | 伊莱利利公司 | 用于治疗idh1抑制剂抗性受试者的方法 |
| MX2022011845A (es) * | 2020-03-23 | 2023-02-16 | Lilly Co Eli | Terapia combinada con un inhibidor de idh mutante y un inhibidor de bcl-2. |
| BR112022017394A2 (pt) | 2020-03-23 | 2022-10-18 | Lilly Co Eli | Terapia de combinação com um inibidor de idh mutante |
| WO2022001916A1 (zh) * | 2020-06-28 | 2022-01-06 | 微境生物医药科技(上海)有限公司 | Idh突变体抑制剂及其用途 |
| CA3186786A1 (en) | 2020-07-20 | 2022-01-27 | David Michael HYMAN | Combination therapy with a mutant idh1 inhibitor, a deoxyadenosine analog, and a platinum agent |
| CN113588768B (zh) * | 2021-05-18 | 2022-07-05 | 国家卫生健康委科学技术研究所 | 一种以分子图像方式定量组织内内源性代谢物的质谱方法 |
| EP4337217A1 (en) | 2021-06-09 | 2024-03-20 | Eli Lilly and Company | Method for treating idh inhibitor-resistant subjects |
| US20240208978A1 (en) * | 2021-06-15 | 2024-06-27 | Wigen Biomedicine Technology (shanghai) Co., Ltd. | Idh mutant inhibitor and use thereof |
| EP4384273A1 (en) | 2021-08-13 | 2024-06-19 | Eli Lilly and Company | Solid forms of 7-[[(1s)-1-[4-[(1s)-2-cyclopropyl-1-(4-prop-2- enoylpiperazin-1-yl)ethyl]phenyl]ethyl]amino]-1-ethyl-4h- pyrimido[4,5-d] [1,3]oxazin-2-one |
| WO2023141087A1 (en) | 2022-01-19 | 2023-07-27 | Eli Lilly And Company | Combination therapy with a mutant idh inhibitor |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201400989TA (en) * | 2011-09-27 | 2014-04-28 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
| CA2903176A1 (en) * | 2013-03-14 | 2014-09-18 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
| WO2014147586A1 (en) * | 2013-03-22 | 2014-09-25 | Novartis Ag | 1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh |
| US10294206B2 (en) * | 2015-04-21 | 2019-05-21 | Forma Tm2, Inc. | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| WO2016171715A1 (en) * | 2015-04-24 | 2016-10-27 | Halliburton Energy Services, Inc. | Methods of fabricating ceramic or intermetallic parts |
| CN107849059B (zh) | 2015-07-27 | 2020-04-28 | 伊莱利利公司 | 7-苯基乙基氨基-4h-嘧啶并[4,5-d][1,3]噁嗪-2-酮化合物及其作为突变体idh1抑制剂的用途 |
| WO2017213910A1 (en) * | 2016-06-06 | 2017-12-14 | Eli Lilly And Company | Mutant idh1 inhibitors |
| CN115109075B (zh) * | 2016-12-16 | 2024-09-20 | 伊莱利利公司 | 突变体idh1和idh2抑制剂 |
-
2017
- 2017-12-08 CN CN202210758386.7A patent/CN115109075B/zh active Active
- 2017-12-08 EA EA201991161A patent/EA036112B1/ru not_active IP Right Cessation
- 2017-12-08 LT LTEP17822882.1T patent/LT3555105T/lt unknown
- 2017-12-08 MD MDE20191188T patent/MD3555105T2/ro unknown
- 2017-12-08 NZ NZ754115A patent/NZ754115A/en unknown
- 2017-12-08 CN CN201780078017.0A patent/CN110072867B/zh active Active
- 2017-12-08 MA MA47399A patent/MA47399B1/fr unknown
- 2017-12-08 ES ES20189241T patent/ES2941631T3/es active Active
- 2017-12-08 JP JP2019532088A patent/JP6793836B2/ja active Active
- 2017-12-08 CA CA3045303A patent/CA3045303C/en active Active
- 2017-12-08 PL PL17822882T patent/PL3555105T3/pl unknown
- 2017-12-08 PT PT178228821T patent/PT3555105T/pt unknown
- 2017-12-08 RS RS20201429A patent/RS61108B1/sr unknown
- 2017-12-08 AU AU2017378060A patent/AU2017378060B2/en active Active
- 2017-12-08 TN TNP/2019/000158A patent/TN2019000158A1/en unknown
- 2017-12-08 EP EP20189241.1A patent/EP3763717B1/en active Active
- 2017-12-08 US US16/349,873 patent/US11001596B2/en active Active
- 2017-12-08 JO JOP/2019/0142A patent/JOP20190142B1/ar active
- 2017-12-08 HU HUE17822882A patent/HUE052067T2/hu unknown
- 2017-12-08 MA MA053881A patent/MA53881A/fr unknown
- 2017-12-08 PH PH1/2019/501328A patent/PH12019501328B1/en unknown
- 2017-12-08 ES ES17822882T patent/ES2835281T3/es active Active
- 2017-12-08 MX MX2019006830A patent/MX2019006830A/es unknown
- 2017-12-08 KR KR1020197016855A patent/KR102276022B1/ko active Active
- 2017-12-08 DK DK17822882.1T patent/DK3555105T3/da active
- 2017-12-08 SI SI201730488T patent/SI3555105T1/sl unknown
- 2017-12-08 UA UAA201905584A patent/UA123640C2/uk unknown
- 2017-12-08 CR CR20190252A patent/CR20190252A/es unknown
- 2017-12-08 PE PE2019001077A patent/PE20190977A1/es unknown
- 2017-12-08 MY MYPI2019003350A patent/MY197313A/en unknown
- 2017-12-08 EP EP17822882.1A patent/EP3555105B1/en active Active
- 2017-12-08 WO PCT/US2017/065246 patent/WO2018111707A1/en active Application Filing
-
2019
- 2019-05-17 ZA ZA2019/03125A patent/ZA201903125B/en unknown
- 2019-05-23 CO CONC2019/0005287A patent/CO2019005287A2/es unknown
- 2019-05-30 SA SA519401897A patent/SA519401897B1/ar unknown
- 2019-06-06 CL CL2019001551A patent/CL2019001551A1/es unknown
- 2019-06-11 DO DO2019000163A patent/DOP2019000163A/es unknown
- 2019-06-11 IL IL267236A patent/IL267236B/en active IP Right Grant
- 2019-06-14 EC ECSENADI201942682A patent/ECSP19042682A/es unknown
-
2020
- 2020-10-29 AU AU2020260493A patent/AU2020260493B2/en active Active
- 2020-11-25 CY CY20201101122T patent/CY1123577T1/el unknown
- 2020-11-26 HR HRP20201882TT patent/HRP20201882T1/hr unknown
-
2021
- 2021-03-16 US US17/202,515 patent/US11649247B2/en active Active
- 2021-03-16 US US17/202,867 patent/US11629156B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI3555105T1 (sl) | Spojine 7-feniletilamino-4H-pirimido(4,5-D)(1,3)oksazin-2-ona kot inhibitorji mutiranih IDH1 in IDH2 | |
| HUS2400019I1 (hu) | KRas G12C inhibotorok | |
| IL287223B1 (en) | kras g12c inhibitors and methods of using them | |
| IL279363A (en) | PCSK9 antagonist compounds | |
| HK1252821A1 (zh) | 用於治療具有rtk突變細胞的患者的組合物和方法 | |
| ZA201802181B (en) | 2¿phenyl¿3,4¿dihydropyrrolo[2,1 ¿f] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof | |
| EP3091984A4 (en) | Substituted benzoxazine and related compounds | |
| EP3230234A4 (en) | Nitrification inhibitor compositions and methods for preparing the same | |
| SG10201902326XA (en) | Mk2 inhibitors and uses thereof | |
| EP3336091A4 (en) | IRAQ4 INHIBITOR AND ITS USE | |
| EP3336090A4 (en) | INHIBITOR OF IRAQ4 AND ITS USE | |
| ZA201704300B (en) | Nitrification inhibitor compositions and methods for preparing the same | |
| PL3310784T3 (pl) | Związki tricykliczne i ich zastosowanie jako inhibitory fosfodiesterazy | |
| HK1257555A1 (zh) | Tec激酶家族之抑制劑 | |
| PT3552017T (pt) | Compostos úteis como inibidores de ripk1 | |
| IL278701A (en) | Heterofused pyridones and their use as IDH inhibitors | |
| EP3233070A4 (en) | Ras-inhibiting indenyl acetamide compounds, compositions, and uses | |
| EP3356357A4 (en) | COMPOSITIONS AND METHODS OF INHIBITING BETA LACTAMASE | |
| EP3568018A4 (en) | COMPOUNDS AND METHOD OF USE | |
| EP3191447A4 (en) | S-imino-s-oxo iminothiazine compounds as bace inhibitors, compositions, and their use | |
| EP3201204A4 (en) | C5-c6-fused tricyclic iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use | |
| EP3192513A4 (en) | 7-fluoro-8-chloro-5 -dibenzo[b,e][1,4]diazepine derivatives and use thereof | |
| TH1501007226A (th) | สารประกอบ 6,7-ไดไฮโดรไพราโซโล[1,5-a]ไพราซีน-4(5H)-โอน และการใช้ของ สิ่งนั้นในฐานะเป็นสารยับยั้งแอลโลสเตอริกของ mGluR2 รีเซ็ปเตอร์ | |
| AU2016901442A0 (en) | Methods and compositions for preventing and/or treating cataracts | |
| AU2014903744A0 (en) | Nitrification inhibitors and formulations |